Cerebrospinal fluid Aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease
Manuscript Number:
16-0722R1
Author(s):
Kaj Blennow, Paolo Eusebi, Anne M. Fagan, Johannes Kornhuber, Piotr Lewczuk, Anja Matzen, José-Luis Molinuevo, John C. Morris, Lucilla Parnetti
Disclosures
Kaj Blennow
Consulting Fees:
Alzheon, Eli Lilly, Fujirebio Europe, IBL International, Novartis, Roche Diagnostics
Paolo Eusebi
Nothing to Disclose
Anne M. Fagan
Consulting Fees:
Member of the Scientific Advisory boards for Roche, IBL International, AbbVie.
Consultant for DiamiR, LabCorp
Johannes Kornhuber
Patents/Royalties
Diagnosis of Alzheimer's disease. WO 2004/092737 A1, 2005.
Immunoglobulin-bound Ab-peptides and immunoglobulins-binding Ab-peptides in diagnosis and therapy of Alzheimer's dementia. WO2007/082750 A1, 2007.
Large Aß-peptide binding particles (LAPS) in diagnosis and therapy of Alzheimer's dementia. EP 1 811 304 A1, 2007
New formulations for diagnosis of Alzheimer's disease. WO 2011/124376 A1, 2011.
Methods of differentially diagnosing dementias. EP 2437067A2, 2012.
Piotr Lewczuk
Consulting Fees:
PL received consultation honoraria from Innogenetics, AJ Roboscreen GmbH, Roche, and Virion\Serion GmbH, and is a member of the Scientific Advisory Board of IBL International.
Grants
Agency:
This study was supported by IBL International GmbH, Hamburg, Germany
Dates:
2015 - 2016
Anja Matzen
Sponsors:
Function: Product Development Specialist
Department: Product Development
José-Luis Molinuevo
Consulting Fees:
Consulting Fees:
IBL International, Roche Diagnostics, Raman Health
John C. Morris
Consulting Fees:
Lilly USA; Takeda Pharmaceuticals
Lucilla Parnetti
Consulting Fees:
Prof. Parnetti received consultation honoraria from IBL as member of the IBL scientific advisory board